Gregorio Benitez
Overview
Explore the profile of Gregorio Benitez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
281
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kaczynski M, Benitez G, Shehadeh F, Mylonakis E, Fiala M
J Gen Intern Med
. 2025 Jan;
PMID: 39838250
Background: Perceived discrimination and medical mistrust are barriers to care that impact both individual and population health. Objective: This study aims to characterize the prevalence of perceived racial or ethnic...
2.
Ventres J, Ting M, Parente D, Rogers R, Norris A, Benitez G, et al.
Open Forum Infect Dis
. 2024 Sep;
11(9):ofae477.
PMID: 39263216
Background: Traditional blood cultures for gram-negative bacteremia can take up to 72 hours or more to return results, prolonging the duration of empiric broad-spectrum intravenous antibiotics. The Accelerate Pheno system...
3.
Kaczynski M, Vassilopoulos A, Vassilopoulos S, Sisti A, Benitez G, Tran Q, et al.
Contemp Clin Trials
. 2024 May;
143:107578.
PMID: 38789079
Background: Early in the pandemic, extensive attention was cast on limited inclusion of historically underrepresented patient populations in COVID-19 clinical trials. How diverse representation improved following these initial reports remains...
4.
Brotherton A, Coroniti A, Ayuninjam D, Sanchez M, Benitez G, Garland J
Open Forum Infect Dis
. 2024 May;
11(5):ofae237.
PMID: 38737433
Background: Rapid initiation of antiretroviral therapy (rapid ART) improves clinical outcomes in people with HIV and is endorsed by clinical guidelines. However, logistical challenges limit widespread implementation. We describe an...
5.
Vassilopoulos A, Kalligeros M, Vassilopoulos S, Shehadeh F, Benitez G, Kaczynski M, et al.
Dig Dis Sci
. 2024 Jan;
69(3):989-1003.
PMID: 38183561
Background: The prevalence of steatotic liver disease (SLD) among patients with rheumatoid arthritis (RA) remains largely unknown. Aims: To investigate the prevalence of SLD and liver fibrosis among patients with...
6.
Vassilopoulos S, Kalligeros M, Vassilopoulos A, Shehadeh F, Benitez G, Kaczynski M, et al.
J Viral Hepat
. 2023 Jun;
30(8):685-693.
PMID: 37309229
Non-alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease. The association between prior hepatitis B virus (HBV), hepatitis A virus (HAV), hepatitis E virus (HEV) infection...
7.
Kaczynski M, Benitez G, Mylona E, Tran Q, Atalla E, Tsikala-Vafea M, et al.
Open Forum Infect Dis
. 2023 May;
10(5):ofad197.
PMID: 37180601
Background: Clinical trials for coronavirus disease 2019 (COVID-19) have struggled to achieve diverse patient enrollment, despite underrepresented groups bearing the largest burden of the disease and, presumably, being most in...
8.
Tran Q, Benitez G, Shehadeh F, Kaczynski M, Mylonakis E
Int J Environ Res Public Health
. 2023 Jan;
20(1).
PMID: 36612967
(1) Background: Respiratory co-infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other viruses are common, but data on clinical outcomes and laboratory biomarkers indicative of disease severity are...
9.
Vassilopoulos A, Shehadeh F, Benitez G, Kalligeros M, Cunha J, Cunha C, et al.
Front Pharmacol
. 2022 Oct;
13:992713.
PMID: 36278224
Biologic (bDMARD) and targeted synthetic (tsDMARD) disease-modifying anti-rheumatic drugs have broadened the treatment options and are increasingly used for patients with psoriatic arthritis (PsA). These agents block different pro-inflammatory cytokines...
10.
Shehadeh F, Benitez G, Mylona E, Tran Q, Tsikala-Vafea M, Atalla E, et al.
J Infect Dis
. 2022 Sep;
227(2):226-235.
PMID: 36056913
Background: Thymosin-α-1 (Tα1) may be a treatment option for coronavirus disease 2019 (COVID-19), but efficacy and safety data remain limited. Methods: Prospective, open-label, randomized trial assessing preliminary efficacy and safety...